What is the risk of hyponatremia with terlipressin, and should it be avoided in a patient with a serum sodium of 124 mEq/L?

Terlipressin and Hyponatremia Risk

Terlipressin carries a significant risk of hyponatremia, including severe cases, and should be used with extreme caution in a patient with sodium of 124 mEq/L—close monitoring is mandatory, and the drug should be discontinued if sodium drops further or symptoms develop.

Understanding the Risk

Hyponatremia is a well-documented adverse effect of terlipressin, reported in postmarketing surveillance 1. The mechanism relates to terlipressin's partial agonist activity at renal vasopressin V2 receptors, despite being designed primarily as a V1 receptor agonist 2.

The incidence is substantial:

• In cirrhotic patients treated for variceal bleeding, 67% experienced a decrease in serum sodium ≥5 mEq/L, with 36% having drops >10 mEq/L 2
• In elderly cirrhotic patients with variceal bleeding, hyponatremia occurred in 68.9%, with moderate-to-severe cases (sodium <130 mEq/L) in 37.8% 3
• The mean sodium decrease was approximately 8 mEq/L in studies 4, 2

Critical risk factors for severe hyponatremia include:

• Lower baseline serum sodium (most important predictor) 4, 2
• Child-Pugh class C cirrhosis (OR 3.12) 3
• Lower albumin levels 4
• Longer duration of terlipressin therapy 4
• Paradoxically, patients with normal or near-normal baseline sodium and lower MELD scores had highest risk of marked drops 2

Specific Guidance for Sodium 124 mEq/L

Your patient with sodium 124 mEq/L falls into a high-risk category. The 2021 Gut guidelines define severe hyponatremia as <125 mmol/L 5, and the 2018 EASL guidelines recommend treatment when sodium is <130 mmol/L 6.

Management approach:

1. If terlipressin is being considered for hepatorenal syndrome (HRS):

   • The FDA label does not list hyponatremia as a contraindication 1
   • However, proceed with heightened vigilance
   • Monitor serum sodium every 4-6 hours initially (not just daily)
   • Consider correcting sodium toward 130 mEq/L before initiating terlipressin if clinically feasible
   • Use judicious albumin administration (avoid excessive volume expansion which worsens hyponatremia) 7

2. If terlipressin is being considered for variceal bleeding:

   • The hemostatic benefit (98.9% success rate) 3 must be weighed against hyponatremia risk
   • Do not withhold terlipressin solely based on sodium 124 mEq/L if active life-threatening bleeding
   • Implement intensive sodium monitoring (every 4-6 hours)
   • Have a plan for rapid intervention if sodium drops further

3. During terlipressin therapy:

   • Discontinue or hold diuretics 5
   • Implement fluid restriction to 1-1.5 L/day 5, 8
   • Avoid hypotonic fluids
   • Stop terlipressin immediately if:
     • Sodium drops to <120 mEq/L 9
     • Patient develops neurological symptoms (confusion, seizures, altered mental status) 2, 10
     • Sodium decreases >10 mEq/L from baseline 2

Critical Pitfalls to Avoid

The rebound phenomenon: Hyponatremia typically develops rapidly (within 24-72 hours) after starting terlipressin 11, 2. More dangerously, sodium can rebound rapidly (>12 mEq/L in 24-48 hours) after stopping terlipressin 12, 2. This rapid overcorrection risks osmotic demyelination syndrome, which occurred in one reported case 2.

Management of rapid rebound:

• If sodium increases >8-10 mEq/L in 24 hours after stopping terlipressin, consider re-administering terlipressin or desmopressin to slow correction 11, 13
• Never allow correction >12 mEq/L per 24 hours 9
• After initial rapid correction of 5 mmol/L in first hour for symptomatic cases, limit to 8 mmol/L per day 6

Patients without cirrhosis are at higher risk: If your patient has prehepatic portal hypertension without cirrhosis, the risk is substantially elevated—27% developed severe fluctuations versus only 4% in cirrhotic patients 12. One such patient developed permanent brain damage 12.

Practical Algorithm

For sodium 124 mEq/L:

• Active variceal bleeding: Use terlipressin with intensive monitoring (sodium q4-6h)
• HRS without active bleeding: Consider correcting sodium to ≥126-128 mEq/L first if time permits, then proceed with terlipressin and intensive monitoring
• Stop terlipressin if: Sodium <120 mEq/L OR drop >10 mEq/L OR neurological symptoms
• After stopping: Monitor sodium q4-6h for 48 hours to catch rebound; intervene if rise >8-10 mEq/L/24h

The bottom line: Terlipressin is not contraindicated at sodium 124 mEq/L, but this patient requires exceptional vigilance with a clear stopping threshold and rebound management plan.